ANSTO nuclear med facility halts production after 2 workers exposed to dangerous radiation dose

The Australian Nuclear Science and Technology Organization (ANSTO)’s new $168 million nuclear medicine facility halted all production after two employees were exposed to an unsafe dose of radiation on Friday, June 21, according to a statement from the organization.

Three workers were “attended to by radiation protection personnel,” according to ANSTO, after contamination was found on the outside of a container which held 42 milliliters of molybdenum-99 (Mo-99).

Two of those employees were exposed to a radiation dose “above the statutory limit.” Early reports suggest that dose was equivalent to a conventional cancer radiation therapy treatment, according to the statement.

“Ansto has launched an urgent investigation after three employees were involved in a safety incident at our brand new nuclear medicine facility,” according to a report by the Guardian. “An investigation commenced on Friday, and both the nuclear regulator, Arpansa, and Comcare have been informed. An estimate of the radiation dose will be confirmed in coming weeks.”

The facility, which was cleared to begin full production of Mo-99 two weeks ago, is located south of Sydney in Lucas Heights.

This is the second incident at the facility in the past few months, the Guardian reported. In March, three staff members at the plant were hospitalized after a pipe malfunctioned exposing them to sodium hydroxide.

""

Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.